ARWR : Summary for Arrowhead Pharmaceuticals, Inc. - Yahoo Finance

U.S. Markets close in 3 hrs 32 mins

Arrowhead Pharmaceuticals, Inc. (ARWR)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
1.89+0.04 (+2.06%)
As of 12:26PM EDT. Market open.
People also watch
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
Previous Close1.85
Bid1.88 x 500
Ask1.89 x 2300
Day's Range1.83 - 1.93
52 Week Range1.20 - 8.22
Avg. Volume1,185,938
Market Cap140.8M
PE Ratio (TTM)-1.61
Earnings DateN/A
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Business Wireyesterday

    Arrowhead Pharmaceuticals Adopts Stockholder Rights Agreement

    Arrowhead Pharmaceuticals Inc. today announced that on March 21, 2017 it entered into a stockholder rights agreement in accordance with an authorization and declaration from its board of directors of a dividend distribution of one preferred share purchase right on each outstanding share of the company’s common stock.

  • Arrowhead Pharmaceuticals, Inc. :ARWR-US: Earnings Analysis: Q1, 2017 By the Numbers : March 21, 2017
    Capital Cube3 days ago

    Arrowhead Pharmaceuticals, Inc. :ARWR-US: Earnings Analysis: Q1, 2017 By the Numbers : March 21, 2017

    Categories: Yahoo Finance Get free summary analysis Arrowhead Pharmaceuticals, Inc. reports financial results for the quarter ended December 31, 2016. We analyze the earnings along side the following peers of Arrowhead Pharmaceuticals, Inc. – Alnylam Pharmaceuticals, Inc, Ionis Pharmaceuticals, Inc., Shire PLC Sponsored ADR, Ligand Pharmaceuticals Incorporated, Johnson & Johnson, Inovio Pharmaceuticals, Inc. and Nanophase Technologies Corporation (ALNY-US, ... Read more (Read more...)

  • Zacks Small Cap Research25 days ago

    SBPH: 2016 Results Sustaining Continued HBV/STING Development

    Spring Bank Pharmaceuticals Inc. (SBPH) filed its fiscal year 2016 10-K on February 15, 2017 in conjunction with a press release highlighting the company’s achievements over the period.  Full-year revenues of $352 thousand were as expected and represent National Institute of Health grants to support the development of SB 9200.  No grant revenue was received in the third or fourth quarter. Fourth quarter expenses were $4.4 million, slightly less than our estimate of $4.5 million.  R&D expenses were $2.8 million, matching our estimate and flat with 4Q:15 levels.  G&A expenses of $1.6 million were $0.1 million behind our estimate, but higher than the $1.3 million for the same period in 2015. Cash and equivalents of $25.5 million rose sequentially from $12.8 million due to the November share issuance, providing sufficient capital to support the company’s development programs until third quarter 2018.